Dutasteride Capsule, Liquid Filled
Product Images NDC 50090-7305

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Dutasteride (NDC 50090-7305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Dutesteride Fig1)

Figure (Dutesteride Fig1)
A line graph showing mean change from baseline AUASI over months of treatment up to 24 months. Two lines compare placebo (solid squares) and dutasteride (open squares), with dutasteride showing a greater decrease over time compared to placebo. The x-axis represents months of treatment, and the y-axis shows mean change from baseline AUASI values.*
FDA Label Image

Figure (Dutesteride Fig2)

Figure (Dutesteride Fig2)
This is a clinical study line graph showing the cumulative percent of patients over 24 months of treatment comparing Dutasteride and placebo groups. The x-axis represents months of treatment, and the y-axis shows the percent of patients. The graph includes cumulative event counts and numbers at risk for both groups at multiple time points.*
FDA Label Image

Figure (Dutesteride Fig3)

Figure (Dutesteride Fig3)
A line graph comparing the cumulative percent of patients over 24 months of treatment between a placebo group and a dutasteride group. The x-axis represents months of treatment (0 to 24), and the y-axis shows percent of patients (0 to 6%). The placebo group line rises more steeply than the dutasteride group. Tables beneath show cumulative events and patients at risk at 0, 6, 12, 18, and 24 months for both groups.*
FDA Label Image

Figure (Dutesteride Fig4)

Figure (Dutesteride Fig4)
A bar chart depicting mean percent change from baseline over months of treatment for Dutasteride 0.5 mg liquid-filled capsules compared to placebo. The x-axis shows treatment duration in months (0, 1, 3, 6, 12, 24), and the y-axis indicates percent change. Bars illustrate changes for placebo and Dutasteride groups at each time point, with sample sizes (n) noted below.*
FDA Label Image

Figure (Dutesteride Fig5)

Figure (Dutesteride Fig5)
A line graph depicting mean change from baseline in mL/sec over 24 months of treatment comparing Dutasteride and placebo. The x-axis shows months of treatment (0 to 24), and the y-axis represents mean change from baseline. Dutasteride shows a steady increase over time, while placebo levels off early. Sample sizes for both groups are listed below the x-axis.*
FDA Label Image

Figure (Dutesteride Fig6)

Figure (Dutesteride Fig6)
A line graph showing mean change from baseline in IPSS over 48 months of treatment for three groups: Dutasteride combined with tamsulosin, Dutasteride 0.5 mg, and Tamsulosin 0.4 mg. The y-axis represents the mean change from baseline in IPSS, and the x-axis shows months of treatment. The graph compares treatment effects over time for each group.*
FDA Label Image

Figure (Dutesteride Fig7)

Figure (Dutesteride Fig7)
A line graph illustrating mean change from baseline in mL/sec over 24 months of treatment. The graph compares three treatments: Dutasteride + tamsulosin, Dutasteride 0.5 mg, and Tamsulosin 0.4 mg. The x-axis represents months of treatment, and the y-axis shows mean change from baseline, with Dutasteride + tamsulosin showing the highest improvement over time.*
FDA Label Image

Chemical Structure (Dutesteride Str)

Chemical Structure (Dutesteride Str)
Chemical structure of Dutasteride, showing the steroid backbone and attached functional groups, including trifluoromethyl-substituted aromatic ring and amide functional groups.*
FDA Label Image

Label Image (Lbl500907305)

Label Image (Lbl500907305)
Dutasteride 0.5 mg liquid filled capsules label from A-S Medication Solutions. The label shows NDC 50090-7305-0 and states the dosage strength as 0.5 mg per capsule. It includes storage instructions to keep between 68 to 77 degrees Fahrenheit and protect from moisture. The bottle contains 30 capsules and is labeled for oral use with directions to see the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.